Arbutus Biopharma Corp Restructuring Charges
Arbutus Biopharma Corp (ABUS) reported Restructuring Charges of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-12
- Arbutus Biopharma Corp restructuring charges for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp restructuring charges for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp restructuring charges for the quarter ending 2025-12-31 was $303.00K, a 218.95% increase year-over-year.
- Arbutus Biopharma Corp restructuring charges for the quarter ending 2025-09-30 was $98.00K, a 97.30% decline year-over-year.
- Arbutus Biopharma Corp restructuring charges for fiscal 2025 was $12.94M, a 247.82% increase from fiscal 2024.
- Arbutus Biopharma Corp restructuring charges for fiscal 2024 was $3.72M.
- Arbutus Biopharma Corp restructuring charges for fiscal 2023 was $0.00.
- Arbutus Biopharma Corp restructuring charges for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month | Restructuring Charges 12 month as first filed | Restructuring Charges 14 month | Restructuring Charges 17 month | Restructuring Charges 21 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $303.00K derived: sum of 3 quarters · filed 2026-08-12 | $401.00K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $303.00K derived: sum of 2 quarters · filed 2026-05-13 | $401.00K derived: sum of 3 quarters · filed 2026-05-13 | $566.00K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $401.00K derived: sum of 2 quarters · filed 2026-03-23 | $566.00K derived: sum of 3 quarters · filed 2026-08-12 | $12.94M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | $98.00K 10-Q · filed 2025-11-13 | $263.00K derived: sum of 2 quarters · filed 2026-08-12 | $12.64M 10-Q · filed 2025-11-13 | $12.73M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $165.00K 10-Q · filed 2026-08-12 | $12.54M 10-Q · filed 2026-08-12 | $12.63M derived: sum of 3 quarters · filed 2026-08-12 | $16.26M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $12.37M 10-Q · filed 2026-05-13 | $12.47M derived: sum of 2 quarters · filed 2026-05-13 | $16.09M derived: sum of 3 quarters · filed 2026-05-13 | $16.09M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.72M derived: sum of 2 quarters · filed 2026-03-23 | $3.72M derived: sum of 3 quarters · filed 2026-03-23 | $3.72M 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $3.63M 10-Q · filed 2025-11-13 | $3.63M derived: sum of 2 quarters · filed 2025-11-13 | $3.63M 10-Q · filed 2025-11-13 | $3.63M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-08-06 | $0.00 derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | $0.00 derived: sum of 3 quarters · filed 2025-05-14 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 | $1.10M 10-K · filed 2024-03-05 | ||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | $0.00 10-K · filed 2022-03-03 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | $0.00 derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | $7.00K derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $7.00K derived: sum of 3 quarters · filed 2022-03-03 | $64.00K 10-K · filed 2022-03-03 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $7.00K derived: sum of 2 quarters · filed 2021-11-04 | $64.00K 10-Q · filed 2021-11-04 | $187.00K derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | $7.00K 10-Q · filed 2021-08-05 | $64.00K 10-Q · filed 2021-08-05 | $187.00K derived: sum of 3 quarters · filed 2021-08-05 | $369.00K derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $57.00K 10-Q · filed 2021-05-05 | $180.00K derived: sum of 2 quarters · filed 2021-05-05 | $362.00K derived: sum of 3 quarters · filed 2021-05-05 | $96.00K derived: sum of 4 quarters · filed 2021-05-05 | ||||
| 2019-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $305.00K derived: sum of 2 quarters · filed 2021-03-04 | $39.00K derived: sum of 3 quarters · filed 2021-03-04 | $156.00K 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | $182.00K 10-Q · filed 2020-11-05 | -$84.00K derived: sum of 2 quarters · filed 2020-11-05 | $33.00K 10-Q · filed 2020-11-05 | $1.12M derived: sum of 4 quarters · filed 2020-11-05 | $4.80M 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | -$266.00K 10-Q · filed 2020-08-07 | -$149.00K 10-Q · filed 2020-08-07 | $938.00K derived: sum of 3 quarters · filed 2020-08-07 | $446.00K derived: sum of 4 quarters · filed 2020-08-07 | $4.70M 10-Q · filed 2019-08-05 | |||
| 2019-03-31 | $117.00K 10-Q · filed 2020-05-11 | $1.20M derived: sum of 2 quarters · filed 2020-05-11 | $712.00K derived: sum of 3 quarters · filed 2020-05-11 | $3.29M derived: sum of 4 quarters · filed 2020-05-11 | $4.90M 10-Q · filed 2019-05-06 | |||
| 2018-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $595.00K derived: sum of 2 quarters · filed 2020-03-05 | $3.18M derived: sum of 3 quarters · filed 2020-03-05 | $4.80M 10-K · filed 2020-03-05 | ||||
| 2018-09-30 | -$492.00K 10-Q · filed 2019-11-06 | $2.09M derived: sum of 2 quarters · filed 2019-11-06 | $3.71M 10-Q · filed 2019-11-06 | $3.71M derived: sum of 4 quarters · filed 2019-11-06 | ||||
| 2018-06-30 | $2.58M 10-Q · filed 2019-08-05 | $4.20M 10-Q · filed 2019-08-05 | $4.20M derived: sum of 3 quarters · filed 2019-08-05 | $4.20M derived: sum of 4 quarters · filed 2019-08-05 | ||||
| 2018-03-31 | $1.62M 10-Q · filed 2019-05-06 | $1.62M derived: sum of 2 quarters · filed 2019-05-06 | $1.62M derived: sum of 3 quarters · filed 2019-05-06 | $1.62M derived: sum of 4 quarters · filed 2019-05-06 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $0.00 10-K · filed 2019-03-07 | ||||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 | ||||||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |